Shattuck Labs, INC Schedule 13D activist filings

Redmile Group, LLC and associated entities have updated their Schedule 13D filing, reporting a beneficial ownership of 9.9% in Shattuck Labs, Inc. as of July 17, 2026.

OrbiMed Advisors filed an amended Schedule 13D reporting its beneficial ownership in Shattuck Labs following a recent public offering.

Redmile Group, LLC and affiliates increased their beneficial ownership in Shattuck Labs, Inc. through warrant exercises and participation in an underwritten offering.

OrbiMed Advisors and its affiliates have acquired a significant stake in Shattuck Labs, Inc. through a private placement, increasing their beneficial ownership to 9.99%.

Redmile Group, LLC increased its beneficial ownership in Shattuck Labs, Inc. to 9.9% following a private placement, while its managing director, Mike Lee, resigned from the board.

Shattuck Labs, Inc. has entered into a private placement agreement with Redmile Group, LLC, granting Redmile significant equity and board observer rights contingent on FDA clearance.